Autogenomics of Carlsbad, Calif., has received US Patent No. 7,429,360, “Level-controlled pipette for automated analytic devices.” The patent claims an automatic pipette for use in an analytic device that uses disposable pipette tips. By properly coupling the pipette tip to the pipette, the accurate volume of the aspirated fluid and distance of the pipette tip to the biochip are determined using a plurality of sensors that are coupled to the automatic pipette, the patent claims.
Hisamitsu Pharmaceutical of Tosu, Japan, and Chiba Prefecture of Chiba, Japan, have received US Patent No. 7,429,451, “Nucleic acids isolated from stage 4 neuroblastoma.” The patent claims an agent or kit for the prognosis of neuroblastoma used to diagnose the prognosis of neuroblastoma, particularly classifying its progress and determining stage four neuroblastomas. The agent or kit includes a nucleic acid probe, nucleic acid primers, and a nucleic acid microarray utilizing a nucleic acid comprising one sequence selected from the group consisting of nucleic acids described in the patent.
Hypromatrix of Worcester, Mass., has received US Patent No. 7,429,466, “Methods and arrays for detecting biological molecules.” The patent claims arrays and methods for detecting one or more biological molecules, that include the steps of: a) providing a first support immobilized with one or more reagents; b) providing a second support immobilized with one or more of ligands; c) contacting the reagents immobilized to the first support with the ligands immobilized on the second support, whereby one or more of the reagents bind to one or more of the ligands; and d) separating the first support from the second support so that one or more of the bound reagents remain bound to one or more ligands on the second support after separation. In one preferred method, proteins are immobilized on a support with adequate strength so that the proteins can be dissociated from the support under certain conditions, such as after binding with other proteins immobilized on another support. For example, antibody arrays produced according to the present invention may be used to detect protein expressions in a protein lysate and may be used in immunostaining to reveal the presence and location of proteins in cells, the patent states.
SRU Biosystems of Woburn, Mass., has received US Patent No. 7,429,492, “Multiwell plates with integrated biosensors and membranes.” The patent describes a multi-well plate that includes: a) a colorimetric resonant reflectance biosensor or a grating-based waveguide biosensor; b) a first liquid impermeable sheet that has two or more holes attached to a top surface of the colorimetric resonant reflectance biosensor or the grating-based waveguide biosensor; c) a membrane attached to the top of the first liquid impermeable sheet, where the membrane covers all of the holes of the first liquid impermeable sheet; d) a multi-well plate frame attached to the top of the membrane, where the multi-well plate frame has two or more holes and where the holes have a same size, number, and position as in the first liquid impermeable sheet; so that e) a multi-well plate with an upper chamber and a lower chamber is formed by the colorimetric resonant reflectance biosensor or the grating-based waveguide biosensor, the first liquid impermeable sheet, the membrane, and the multiwell plate frame.
GNI of Tokyo has received US Patent No. 7,430,475, “Biological discovery using gene regulatory networks generated from multiple-disruption expression libraries.” The patent describes inferential methods for the analysis of complex biological information, including gene networks, where disruptive data or drug induction and inhibition data are obtained simultaneously for a number of genes in an organism. The described methods include modifications of Boolean inferential methods and application of those methods to determining relationships between expressed genes in organisms. Other described methods include modifications of Bayesian inferential methods and application of those methods to determining cause and effect relationships between expressed genes, and in some embodiments, for determining upstream effectors of regulated genes. Additional modifications of Bayesian methods include use of heterogeneous variance and different curve-fitting methods, including spline functions, to improve estimation of graphs of networks of expressed genes.